Fulgent Genetics, Inc. (FLGT): Cost of Revenue
$191.80M
Year ended 2025-12-31
$208.67M
Trailing 12 months to 2026-06-30
-8.7%
3-year compound annual growth
+16.4%
5-year compound annual growth
+43.8%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $191.80M | +8.8% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $176.25M | -4.6% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $184.76M | -26.7% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $252.07M | +17.0% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $215.53M | +140.0% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $89.81M | +536.6% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $14.11M | +31.9% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $10.70M | +25.1% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $8.55M | +27.2% | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | $6.72M | +32.6% | 2018-03-20, From 2016-01-01 |
| 2015-12-31 | $5.07M | +441.6% | 2017-03-17, From 2015-01-01 |
| 2014-12-31 | $936.0K | n/a | 2017-03-17, From 2014-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $191.80M | +8.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $96.65M | +34.9% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $71.03M | +18.0% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $349.01M | +20.4% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $53.87M | -6.8% |
| Exagen Inc. (XGN) | 2025-12-31 | $27.78M | +23.3% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $23.02M | +20.2% |
| Quest Diagnostics Inc (DGX) | 2025-12-31 | $7.37B | +11.2% |
| Labcorp Holdings Inc. (LH) | 2025-12-31 | $9.94B | +5.9% |
Compare FLGT, BLLN, CSTL, GH side by side · Screen every company in Services-Medical Laboratories ↗